Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Key Points

• Intellia Therapeutics is set to announce its Q2 2025 earnings on August 7, expecting a loss of $1.03 per share and revenue of $12.26 million, with analysts projecting a surprising increase from the previous quarter's report.
• The company's last quarterly report showed a revenue of $16.63 million, surpassing expectations, despite a significant decline of 42.6% year-over-year.
• An increase in institutional ownership was noted, with major investors like UBS Asset Management and AQR Capital Management raising their positions in Intellia Therapeutics during the first quarter.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.03) per share and revenue of $12.26 million for the quarter.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. The firm had revenue of $16.63 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the business posted ($1.12) earnings per share. The firm's revenue was down 42.6% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock traded down $0.23 during trading on Friday, reaching $11.42. 2,205,276 shares of the company were exchanged, compared to its average volume of 4,033,797. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $24.25. The company has a market capitalization of $1.18 billion, a P/E ratio of -2.18 and a beta of 2.21. The stock's 50 day simple moving average is $10.21 and its two-hundred day simple moving average is $9.43.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 12,534 shares of company stock valued at $153,837. Company insiders own 3.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock valued at $3,709,000 after purchasing an additional 38,521 shares during the period. Woodline Partners LP purchased a new position in Intellia Therapeutics in the first quarter valued at about $171,000. Finally, AQR Capital Management LLC raised its position in Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company's stock valued at $646,000 after purchasing an additional 55,118 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of research analyst reports. Wedbush restated a "neutral" rating and issued a $7.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 16th. Wolfe Research raised Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price for the company in a research note on Monday, April 21st. Chardan Capital reaffirmed a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a research report on Friday, May 9th. Canaccord Genuity Group lowered their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 16th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.37.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.